Pharm-Olam completes birch and grass pollen allergy studies

Pharm-Olam provided a full-service solution for two Phase II, dose escalation allergy studies, Grass Pollen & Birch Pollen.

FEBRUARY 1, 2014

Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe. With two different allergy indications, Grass Pollen and Birch Pollen, these studies presented some unique challenges.

To read full case study to learn more about the challenges encountered and the solutions Pharm-Olam implemented, click here.

Share this: